---
schema_version: "secwatch.filing_event.v1"
accession: "0001601485-26-000026"
form_type: "8-K"
ticker: "ELTX"
cik: "0001601485"
company_name: "Elicio Therapeutics, Inc."
filed_at: "2026-03-12T23:59:59+00:00"
generated_at: "2026-05-15T13:25:02.795137+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Elicio Therapeutics reports FY2025 net loss of $39.5M; Phase 2 PDAC trial DFS readout expected 1H 2026

## Summary
- Net loss for 2025 was $39.5M ($2.58 per share), compared to $51.9M ($4.25) in 2024.
- R&D expense decreased to $24.9M from $33.7M; G&A expense increased to $12.8M from $11.3M.
- Cash and equivalents $18.6M as of Dec 31, 2025; runway into Q3 2026 beyond expected Phase 2 DFS analysis.
- Phase 2 AMPLIFY-7P trial in PDAC: fewer progressions and deaths observed than projected; primary DFS analysis on track for 1H 2026.
- Raised net ~$4.9M in Q4 2025 and ~$6.3M in Q1 2026 via at-the-market program; appointed Marc J. Wolfgang as CTO.

## SEC filing metadata
- accession: 0001601485-26-000026
- form_type: 8-K
- ticker: ELTX
- cik: 0001601485
- company_name: Elicio Therapeutics, Inc.
- filed_at: 2026-03-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1601485/000160148526000026/0001601485-26-000026-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1601485/000160148526000026/angn-20260312.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001601485-26-000026
- JSON: https://secwatch.observer/filing/0001601485-26-000026.json
- Plain text: https://secwatch.observer/filing/0001601485-26-000026.txt

## Key facts
- Earnings Releases
  Elicio Therapeutics, Inc. reported the year ended December 31, 2025 results: net income $39.5 million, EPS $2.58.
  - Period: the year ended December 31, 2025
  - Net income: $39.5 million
  - EPS: $2.58
  - Result: reported results
  source text: Net loss for 2025 was $39.5 million, compared to $51.9 million for 2024. Net loss for 2025 includes $1.9 million of non-cash other expense resulting from the change in fair value of the warrant liability. Net loss per share for 2025 was $2.58, compared to $4.25 for 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1601485/000160148526000026/0001601485-26-000026-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.